Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mizagliflozin Formulations in Post-Bariatric Hypoglycemia
NCT05541939Phase 2Completed
- Sponsor
- Vogenx
- Start
- Sep 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mizagliflozin in post-bariatric hypoglycemia (PBH) (2 arms), sponsored by Vogenx. Primary endpoint: Glucose Nadir After Mizagliflozin Dosing. Started Sep 2022; status: completed.
02
Drugs
mizagliflozin
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NCT05541939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05541939.